Literature DB >> 12897728

Allergic and nonallergic forms of atopic diseases.

Natalija Novak1, Thomas Bieber.   

Abstract

Atopic dermatitis, allergic rhinitis, and asthma are atopic diseases that develop on a complex genetic background, the so-called atopic diathesis. Although they target different organs, in most patients they are characterized by the presence of elevated total serum IgE levels. However, a subgroup of atopic patients exhibits normal IgE levels and mechanisms contributing to the so-called "intrinsic" or "nonallergic form" have been the matter of intensive research work in the last years. Because of the rapid advancements in the research field of atopic diseases, it now becomes possible for the first time to delineate a new disease classification of allergic and nonallergic subtypes of atopic diseases, thereby bringing hope to the clinician for a more specific treatment approach for each subgroup of these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897728     DOI: 10.1067/mai.2003.1595

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  64 in total

1.  Type 2 helper T-cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalent.

Authors:  Marijke Kamsteeg; Mieke Bergers; Roelie de Boer; Patrick L J M Zeeuwen; Stanleyson V Hato; Joost Schalkwijk; Geuranne S Tjabringa
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Lessons from murine models of atopic dermatitis.

Authors:  Tao Zheng; Zhou Zhu
Journal:  Curr Allergy Asthma Rep       Date:  2005-07       Impact factor: 4.806

3.  Mechanisms of anti-carcinogenesis by indole-3-carbinol. Studies of enzyme induction, electrophile-scavenging, and inhibition of aflatoxin B1 activation.

Authors:  A T Fong; H I Swanson; R H Dashwood; D E Williams; J D Hendricks; G S Bailey
Journal:  Biochem Pharmacol       Date:  1990-01-01       Impact factor: 5.858

4.  Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Authors:  Rui Zhu; Yanan Zheng; Wendy S Putnam; Jennifer Visich; Mark D Eisner; John G Matthews; Karin E Rosen; David Z D'Argenio
Journal:  AAPS J       Date:  2013-02-15       Impact factor: 4.009

Review 5.  Allergen Immunotherapy and Atopic Dermatitis: the Good, the Bad, and the Unknown.

Authors:  Patrick Rizk; Mario Rodenas; Anna De Benedetto
Journal:  Curr Allergy Asthma Rep       Date:  2019-11-27       Impact factor: 4.806

6.  Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression.

Authors:  Michiko K Oyoshi; Ryan P Larson; Steven F Ziegler; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2010-11       Impact factor: 10.793

7.  Suppression of cytokine gene expression and improved therapeutic efficacy of microemulsion-based tacrolimus cream for atopic dermatitis.

Authors:  Manisha S Lalan; Naresh C Laddha; Jigar Lalani; Muhammad J Imran; Rasheedunnisa Begum; Ambikanandan Misra
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

8.  Relationships between levels of serum IgE, cell-bound IgE, and IgE-receptors on peripheral blood cells in a pediatric population.

Authors:  Eleonora Dehlink; Alexandra H Baker; Elizabeth Yen; Samuel Nurko; Edda Fiebiger
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

9.  Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis.

Authors:  Mayte Suárez-Fariñas; Nikhil Dhingra; Julia Gittler; Avner Shemer; Irma Cardinale; Cristina de Guzman Strong; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2013-06-15       Impact factor: 10.793

10.  The imbalance in serum concentration of Th-1- and Th-2-derived chemokines as one of the factors involved in pathogenesis of atopic dermatitis.

Authors:  Joanna Narbutt; Aleksandra Lesiak; Anna Sysa-Jedrzeiowska; Marcin Zakrzewski; Jarosław Bogaczewicz; Iwona Stelmach; Piotr Kuna
Journal:  Mediators Inflamm       Date:  2009-07-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.